Trial · NCT02307474
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
NCT02307474, Not applicable, Withdrawn, Case Comprehensive Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer. Trials, record NCT02307474. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02307474
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
- NCT number
- NCT02307474
- Status
- Withdrawn
- Phases
- Not applicable
- Enrollment
- 0 participants, actual
- Lead sponsor
- Case Comprehensive Cancer Center
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
- Interventions
- Stereotactic Radiosurgery, Pazopanib Hydrochloride
- First posted
- 2014-12-04
- Last updated
- 2016-03-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of grade 3 and above National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 toxicity attributed to combination treatment | Up to 180 days post-SBRT | The toxicity profiles will be tabulated by follow-up period (i.e. 30 days and 180 days). |
| Secondary | Response rate, assessed using RECIST | Up to 24 months | Estimated based on the number of responses using a binomial distribution and its confidence intervals will be estimated using Wilson's method. Factors including patient characteristics that predict response will be identified by logistic regression. |
| Secondary | Change in tumor volume | Baseline to up to 24 months | Summarized by mean ± standard deviation and the difference between two time points (pre and post treatment) will be examined using paired T-test. |
| Secondary | Disease-free survival | From the start of treatment to the date of disease progression or the date of death, whichever comes first, assessed up to 24 months | Summarized by calculating Kaplan-Meier curves. Survival rates estimated from the Kaplan-Meier curves will be estimated with 95% confidence intervals. |
| Secondary | Overall survival | From the start of treatment to the date of death, assessed up to 24 months | Summarized by calculating Kaplan-Meier curves. Survival rates estimated from the Kaplan-Meier curves will be estimated with 95% confidence intervals. |
| Secondary | Time to local progression | From the start of treatment to the date of local progression, assessed up to 24 months | Summarized by calculating Kaplan-Meier curves. Survival rates estimated from the Kaplan-Meier curves will be estimated with 95% confidence intervals. |
| Secondary | Time to distant failure | From the start of treatment to the date of distant metastases, assessed up to 24 months | Summarized by calculating Kaplan-Meier curves. Survival rates estimated from the Kaplan-Meier curves will be estimated with 95% confidence intervals. |
| Secondary | Rate of acute side effects | Up to 180 days after treatment | Summarized as a proportion with 95% confidence intervals. |
| Secondary | Rate of late side effects | Up to 24 months | Summarized as a proportion with 95% confidence intervals. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | SCHWARTZ, GARY K | CASE WESTERN RESERVE UNIVERSITY | NATIONAL CANCER INSTITUTE | 1987 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02307474
GET https://conductscience.org/api/trials/v1/NCT02307474/registered